Food for Thought: Make Room for Multiple Opinions in DOL Strategy

The rise of the DOL doesn’t mean pharma should upend KOL approach.

By Read Roberts

With the rise of DOL influence, clients are asking whether their strategies
should focus specifically on DOLs in place of KOLs? We have found that both
groups are important. Although differences do exist between KOLs and DOLs, they
share commonalities. And reaching both may be easier than you think……

More in the complete article here on Pharm,

Published on  March 10, 2023, Pharmaceutical Executive, March 2023, Volume 43, Issue 2

Download full Pharmaceutical Executive March 2023 Issue

For more on our KOL Data Solutions and DOL tools

Accelerating clinical research and development through the combined power of trials, labs, and data science.

Demonstrating the value of life-science innovations with evidence and real-world expertise.